Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Year ended March 31, 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Audited Financial Results and Dividend Recommendation

Date of Board Meeting / Approval: May 29, 2026 (commenced at 04:30 p.m., concluded at 07:26 p.m.)

Audit Opinion: Unmodified opinion from Walker Chandiok & Co LLP

Auditor’s Comment: No qualifications or modifications affecting earnings quality, internal controls, or going concern.

Key Financial Highlights [All amounts in million Indian Rupees]

Standalone Results:

Quarter ended 31/03/2026:

  • Revenue from Operations: ₹37,705.86
  • Total Income: ₹39,596.69
  • Net Profit/(Loss): (₹739.02)
  • EPS (Basic): (₹2.62)
  • EPS (Diluted): (₹2.62)

Year ended 31/03/2026:

  • Revenue from Operations: ₹1,69,825.11
  • Total Income: ₹1,74,431.30
  • Net Profit/(Loss): (₹2,007.99)
  • EPS (Basic): (₹7.12)
  • EPS (Diluted): (₹7.11)
  • Other Equity: ₹2,41,221.04
  • Cash and Cash Equivalents: ₹2,918.31
  • Debt: Not separately specified in standalone results

Consolidated Results:

Quarter ended 31/03/2026:

  • Revenue from Operations: ₹37,705.86
  • Total Income: ₹39,596.69
  • Net Profit: ₹3,014.14 (attributable to owners)
  • EPS (Basic): ₹10.68
  • EPS (Diluted): ₹10.68

Year ended 31/03/2026:

  • Revenue from Operations: ₹1,69,825.11
  • Total Income: ₹1,74,431.30
  • Net Profit: ₹13,618.51 (attributable to owners)
  • EPS (Basic): ₹48.26
  • EPS (Diluted): ₹48.24
  • Other Equity: ₹1,04,838.89
  • Cash and Cash Equivalents: ₹11,747.09
  • Debt: Short-term borrowings ₹16,814.95; Long-term borrowings ₹5,127.00

Financial Performance Comparison:

Standalone results show material deterioration with a net loss of ₹2,007.99M for FY26 compared to a net profit of ₹16,103.50M in FY25, primarily due to exceptional items. Consolidated results show improvement with net profit of ₹13,618.51M for FY26 compared to ₹10,470.97M in FY25.

Segment-wise Performance:

The Chief Operating Decision Maker reviews performance at the pharmaceutical business level, comprising generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent. Therefore, the Company has only one reportable segment: Pharmaceuticals.

Corporate Actions:

  • Board recommended a final dividend of 250% i.e. ₹2.5 per equity share (face value of ₹1 each) for FY25-26
  • Dividend payment is subject to approval of shareholders at the ensuing Annual General Meeting
  • No share split, bonus issue, buyback, or capital raising announced

Exceptional Items [Non-Recurring]:

Standalone and Consolidated for 31.03.2026:

  • Provision of ₹3,232.32M for settlement with putative direct purchaser class in US antitrust litigation
  • Provision of ₹2,780.70M for settlement with state attorney general in US antitrust litigation
  • Settlement of ₹976M with United Healthcare Services, Inc. for last en-payor plaintiff claims
  • Other exceptional items include: provision on certain inventories (₹5,901M), receivables and other current assets (₹4,958.32M), impairment of property, plant and equipment (₹2,278.91M), and legal costs (₹1,394.68M)
  • Provision of ₹1,130.73M (standalone) and ₹1,138.91M (consolidated) for employee benefits due to implementation of New Labour Codes

Standalone and Consolidated for 31.03.2025:

  • Settlement cost of ₹598.15M with Humana, Centene, and Kaiser who opted out of 2023 settlements
  • Other associated legal costs of ₹1,749.99M
  • Restructuring loss of ₹1,978.20M from IGI TSA innovation arm closure and facility shutdown

Other Significant Information:

  • Previous period figures have been re-grouped/re-classified for comparability
  • Figures for quarters ended March 31, 2026 and 2025 are balancing figures between audited full year and unaudited published figures up to nine months
  • Diluted EPS computed considering effect of conversion of ESOPs
  • The company denies all allegations in the litigation matters and settlements are commercial without admission of liability

Entities in Consolidation:

The consolidated financial statements include 43 subsidiaries as listed in Annexure A, including operations in USA, Europe, Latin America, Africa, Asia, and Australia.